InMed Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 13, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Unaudited Condensed Consolidated Interim Financial Statements of
For the Three and Six Months Ended December 31, 2023 and 2022
Suite 310 – 815 West Hastings Street
Vancouver, BC, Canada, V6C 1B4
Tel: +1-604-669-7207
(Expressed in U.S. Dollars)
December 31, 2023
| INDEX | Page | |
|---|---|---|
| Financial Statements (Unaudited) | ||
| ● | Condensed Consolidated Interim Balance Sheets | 3 |
| ● | Condensed Consolidated Interim Statements of Operations | 4 |
| ● | Condensed Consolidated Interim Statements of Shareholders’ Equity | 5 |
| ● | Condensed Consolidated Interim Statements of Cash Flows | 6 |
| ● | Notes to the Condensed Consolidated Interim Financial Statements | 7-22 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.